Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool November 19, 2010 Brian Orelli	One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales.
The Motley Fool February 9, 2010 Brian Orelli	Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status.
The Motley Fool January 28, 2008 Brian Lawler	A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.
BusinessWeek April 19, 2004 Gene G. Marcial	NPS: Ripe For A Buyout Little-known NPS Pharmaceuticals, which develops recombinant proteins to treat bone, gastrointestinal, and nervous disorders, is catching the eye of Big Pharma with its pipeline of products.
The Motley Fool September 2, 2009 Robert Steyer	Pharma's Next Home Run Drug Could Be 4 Singles Instead With mixed success in the women's health field, drugmakers try to turn a single compound into a treatment for several diseases and conditions.
The Motley Fool June 2, 2010 Brian Orelli	Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market.
The Motley Fool October 26, 2010 Brian Orelli	Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth.
Nurse Practitioner June 2009 Ivy M. Alexander	Pharmacotherapeutic management of osteoporosis and osteopenia The estimated number of individuals with osteoporosis and osteopenia, the precursor to osteoporosis, continues to increase.
The Motley Fool July 8, 2009 Brian Orelli	Amgen Closes In on a Home Run Amgen already had a ball flying high above the outfield in its osteoporosis treatment, denosumab, but yesterday's clinical trial results were the wind that could push it out of the park.
The Motley Fool October 7, 2004 Charly Travers	Amgen's Next Blockbuster An osteoporosis drug could give the company its next big winner. With a P/E back in the mid 20s, the company is valued such that Amgen shareholders should be rewarded in the future if products are successful.
The Motley Fool February 26, 2010 Brian Orelli	Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market.
The Motley Fool June 13, 2008 Brian Lawler	Lilly Patches Its Pipeline An early-stage compound joins the pharmaceutical's upcoming roster.
BusinessWeek June 21, 2004 Catherine Arnst	Guard Your Bones Osteoporosis is one of the biggest health risks facing older women. What can be done to help prevent this disease?
The Motley Fool January 25, 2011 Brian Orelli	2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform.
Pharmaceutical Executive October 1, 2008 Joanna Breitstein	The D-Mab Men Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug for the multi-billion dollar osteoporosis market
The Motley Fool September 20, 2007 Billy Fisher	More Options for Healthy Bones? Novartis and Wyeth might be able to offer alternative treatments for osteoporosis, but the companies have a tough road ahead in this market.
The Motley Fool September 17, 2007 Brian Orelli	Preventing Cancer, No Bones About It For Eli Lilly, the only thing better than having a drug with more than $1 billion in annual sales is getting it approved to treat more patients. That's what just happened with their cancer drug, EVISTA. Investors, take note.
The Motley Fool February 9, 2011 Luke Timmerman	Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"?
The Motley Fool March 25, 2009 Brian Orelli	The FDA Leaves Pfizer in the Waiting Room The EU loves its new osteoporosis drug, but what about the U.S.?
The Motley Fool August 19, 2009 Brian Orelli	Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug.
The Motley Fool January 8, 2008 Brian Orelli	A Painful Reminder From the FDA The agency issues a reminder that osteoporosis drugs can cause severe pain.
The Motley Fool December 10, 2010 Brian Orelli	Something Is Better Than Nothing, I Guess Novartis' Zometa fails a critical clinical trial.
The Motley Fool March 11, 2010 Brian Orelli	FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope.
American Family Physician October 1, 2004 Thomas M. Zizic	Pharmacologic Prevention of Osteoporotic Fractures Of the drugs that have been approved for the prevention or treatment of osteoporosis, the bisphosphonates (risedronate and alendronate) are most effective in reducing the risk of vertebral and nonvertebral fractures.
HHMI Bulletin May 2011 Dan Ferber	Revealing the Biological Complexity of Bones Bones are the body's framework and support, our strongest tissues. Unlike the scaffold of a building, however, bones are anything but inert. They pulse with life and their maintenance requires a surprisingly delicate balancing act.
The Motley Fool September 17, 2008 Brian Orelli	Will Denosumab Strengthen Amgen's Bones? Recently passing its phase 3 trial will help get denosumab on the market. But two big questions remain: how well it worked, and whether anyone will buy it, given the drug's plentiful rivals.
American Family Physician April 15, 2004 Bazaldua & Bruder	STEPS Drug Update Teriparatide (Forteo) for Osteoporosis
The Motley Fool August 14, 2009 Brian Orelli	Amgen Close to Scoring Big Amgen gets good-enough results from a FDA panel.
BusinessWeek August 13, 2009 Arlene Weintraub	Amgen's Bone-Loss Drug Faces Marketing Hurdles Amgen is likely to receive FDA approval for denosumab, its new biologic bone-loss drug, but it may be a hard sell against cheaper generics.
The Motley Fool July 31, 2009 Brian Orelli	Make Money Off Baby Boomers They're getting older whether they like it or not and need blood pressure, osteoporosis, and arthritis drugs and therapies.
The Motley Fool September 10, 2008 Brian Lawler	A Pfizer Drug With a Cloudy Future The company offers another drug with mixed odds to the FDA.
American Family Physician March 15, 2001 Jeannette E. South-Paul	Osteoporosis: Part II. Nonpharmacologic and Pharmacologic Treatment Family physicians will frequently encounter patients with osteoporosis, a condition that is often asymptomatic until a fracture occurs...
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
The Motley Fool October 19, 2009 Brian Orelli	Still Waiting for Its Blockbuster Amgen announces a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia, its treatment for postmenopausal osteoporosis.
The Motley Fool April 21, 2011 Luke Timmerman	Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis.
American Journal of Nursing August 2011 Karen Roush	Prevention and Treatment of Osteoporosis in Postmenopausal Women: A Review This article provides an overview of osteoporosis, describes current recommendations for its prevention and treatment, and discusses nursing implications.
BusinessWeek January 14, 2010 Rob Waters	Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology.
The Motley Fool August 6, 2007 Andrew R. Vaino	NPS Pharmaceuticals: What's for Dinner? The small biotech pins its hopes on a drug that helps patients digest their food. Because the company's market cap is just $180 million, shares could jump significantly on a positive clinical result.
Chemistry World January 26, 2015 Phillip Broadwith	Shire deepens rare disease focus with NPS buyout UK specialty pharmaceutical firm Shire has agreed to buy US biotech NPS Pharmaceuticals for $5.2 billion.
American Family Physician April 1, 2003 Campion & Maricic	Osteoporosis in Men Osteoporosis in men is now recognized as an increasingly important public health issue. Increased awareness by physicians of risk factors for male osteoporosis -- and early diagnosis and treatment -- are needed to decrease the morbidity and mortality resulting from osteoporotic fractures.
American Family Physician March 1, 2004	Osteoporosis The definition, signs, and who's at risk of getting osteoporosis.
The Motley Fool October 24, 2008 Brian Orelli	Amgen's Back Shares of Amgen are up 40% from their lows in March. And for good reason.
The Motley Fool June 11, 2007 Brian Lawler	More Air for Alkermes The biopharmaceutical drug delivery expert brings another drug into clinic stage testing. Investors, take note.
Chemistry World May 8, 2007 Lionel Milgrom	Yearly Anti-Osteoporosis Jab Goes Straight to the Bone One injection of a new anti-osteoporosis drug a year can stop osteoporotic bone fractures in post-menopausal women, report researchers. The drug is already marketed by Novartis as Zometa (zoledronic acid) for use in several other disorders.
American Family Physician March 1, 2001 Jeannette E. South-Paul	Osteoporosis: Part I. Evaluation and Assessment Because osteoporosis is usually asymptomatic until a fracture occurs, family physicians must identify the appropriate timing and methods for screening those at risk...
BusinessWeek May 15, 2006 Arlene Weintraub	Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.
The Motley Fool October 20, 2005 Brian Gorman	Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors.
American Family Physician March 1, 2001	What You Should Know About Osteoporosis What is osteoporosis?... Who gets osteoporosis?... What are the effects of osteoporosis?... How does my doctor know I have osteoporosis?... How is osteoporosis treated?... How is osteoporosis prevented?... etc.